杏十八新茶分享

 

In Re: Rigel Pharmaceuticals

Summarized by:

  • Court: 9th Circuit Court of Appeals Archives
  • Area(s) of Law: Civil Law
  • Date Filed: 09-06-2012
  • Case #: 10鈥17619
  • Judge(s)/Court Below: Circuit Judge Hug for the Court; Circuit Judges B. Fletcher and Paez

District court did not err by granting defendants鈥 motion to dismiss because plaintiffs failed to sufficiently plead securities violations for misleading and fraudulent statements issued by a drug development company in relation to their 2008 stock offering.

Inter-Local Pensions Fund filed suit for securities fraud, individually and on behalf of common stock purchasers of Rigel Pharmaceuticals, Inc. (Rigel), for violations of the Securities Exchange Act. The complaint alleged that Rigel and others (collectively 鈥淒efendants鈥) made false or misleading statements regarding their registration and prospectus statements issued in relation to their 2008 stock offering. The district court granted Defendants鈥 motion to dismiss, finding that the complaint did not 鈥渟ufficiently allege a false or misleading statement or omission and failed to sufficiently allege scienter[.]鈥 Plaintiffs appealed. The Ninth Circuit held that the complaint did not sufficiently allege misstatements in connection with partnership prospects and did not sufficiently plead scienter, which requires showing a 鈥渟trong inference鈥 that Defendants intended to deceive by making fraudulent or misleading statements. Additionally, the Court ruled that Plaintiffs鈥 Section 11 claims, creating a remedy under the Securities Act for registration misstatements, were based in fraud, and, therefore, did not meet the particularity pleading requirements to sufficiently allege fraud. AFFIRMED.

Advanced Search


Back to Top